Opca Bolnica Dubrovnik
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The oncology department at Opca Bolnica Dubrovnik is conducting research on heart‑related conditions, with a focus on Acute myocardial infarction. The trial aims to assess a self‑administered medication that could be used when symptoms of a heart attack appear, seeking to improve rapid response and reduce recurrent events.
- Self‑administration of emergency therapy
- Safety and tolerability evaluation
- Impact on recurrence risk
This work complements the site’s broader oncology program, offering patients a potential new option for managing acute cardiac events.
Neoplasms
Clinical studies at the center target advanced Non‑small cell lung cancer (NSCLC), exploring innovative combinations of immunotherapy and targeted agents. One trial investigates the addition of Adagrasib to standard chemotherapy and pembrolizumab for patients with the KRAS G12C mutation, while another compares a novel antibody combo against conventional docetaxel therapy.
- Immunotherapy‑based combination regimens
- Targeted treatment for KRAS‑mutated tumors
- Second‑ and third‑line therapeutic strategies
These investigations aim to extend survival and improve quality of life for individuals facing metastatic lung cancer.
Respiratory Tract Diseases
The site’s research portfolio also includes a study on Chronic Obstructive Pulmonary Disease (COPD). Participants receive two dose levels of an inhaled agent, CHF6001, added to their existing triple therapy (ICS, LABA, LAMA) to determine whether exacerbations can be reduced over a year-long period.
- Add‑on inhaled therapy evaluation
- Reduction of moderate and severe COPD exacerbations
- Long‑term safety and tolerability monitoring
By enhancing standard maintenance treatment, the trial seeks to provide better disease control for patients with chronic respiratory illness.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 3 therapeutic areas and 15 of 27 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 60 other sites in Croatia
Therapeutic Area Benchmark — Croatia
Select a therapeutic area to compare against other sites in Croatia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Croatia
Market Share
Country: Croatia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Opca Bolnica Dubrovnik
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | Janssen Cilag International | Phase III | Not Recruiting | Aug 2023 | — |
IMP list
lock Showing 1 of 27 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 3 | Unknown | 2024-10-01 | 2025-06-12 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.